- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03947346
Biomarkers of Renal Dysfunction in Neuroblastoma Survivors
March 18, 2024 updated by: Memorial Sloan Kettering Cancer Center
The main purpose of this study is to learn more about biomarkers of kidney function in the blood and urine of neuroblastoma survivors.
A biomarker is a biological molecule found in blood, urine, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.
A biomarker may be used to see how well the body responds to a treatment for a disease or condition.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
28
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 20 years (Child, Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Childhood cancer survivors followed by the Pediatric Long-Term Follow-Up (LTFU) Program will be recruited for the current study.
Description
Inclusion Criteria:
- Diagnosis of neuroblastoma between 0-18 years of age
- < 21 years of age at time of study enrollment
- Two or more years from completion of systemic chemotherapy and/or radiation therapy
Exclusion Criteria:
- Patients treated with observation only
- Patients with multiple primary cancers
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
survivors of neuroblastoma treated with nephrotoxic therapy
Upon enrollment, all subjects will receive a urine collection kit by mail.
Participants will bring in a first-morning urine specimen on the day of their routinely scheduled long-term follow-up visit, and will then have an additional blood and urine sample drawn with their other clinical care labs upon arrival to MSK.
|
The urine collected from the first morning void will be used to assess urine creatinine and microalbumin.
The fresh urine specimen will be analyzed for novel urinary biomarkers of (urinary NGAL, TGF-β1, IL-18 and KIM-1).
Serum BUN, creatinine, and cystatin-C will be assessed using serum samples drawn for routine clinical care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
indicators of renal injury
Time Frame: 2 years
|
urine collected from the first morning void will be used to assess urine creatinine
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Danielle Friedman, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 9, 2019
Primary Completion (Estimated)
May 1, 2025
Study Completion (Estimated)
May 1, 2025
Study Registration Dates
First Submitted
May 9, 2019
First Submitted That Met QC Criteria
May 9, 2019
First Posted (Actual)
May 13, 2019
Study Record Updates
Last Update Posted (Actual)
March 19, 2024
Last Update Submitted That Met QC Criteria
March 18, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Kidney Diseases
- Urologic Diseases
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroectodermal Tumors, Primitive
- Neuroectodermal Tumors, Primitive, Peripheral
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Renal Insufficiency
- Neuroblastoma
Other Study ID Numbers
- 19-160
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials.
The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov
when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required.
Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication.
Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals.
Requests may be made to: crdatashare@mskcc.org.
IPD Sharing Supporting Information Type
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroblastoma Survivors
-
Memorial Sloan Kettering Cancer CenterCompletedAdolescent Cancer Survivors | Pediatric Cancer SurvivorsUnited States
-
The First Affiliated Hospital of Soochow UniversityRecruitingSurvivors of Young Male Cancer SurvivorsChina
-
Memorial Sloan Kettering Cancer CenterCompletedCancer Survivors | Statin Use Among High Risk SurvivorsUnited States
-
Thaddeus PaceCompletedCancer Survivors | Informal Cancer Caregivers (Family and Friends of Cancer Survivors)United States
-
University of CalgaryCompleted
-
Azienda Unità Sanitaria Locale Reggio EmiliaRecruiting
-
University of New MexicoNational Cancer Institute (NCI)Active, not recruiting
-
Virginia Commonwealth UniversityCompleted
-
University of ArizonaNot yet recruitingNeoplasms | Cancer SurvivorsUnited States
Clinical Trials on Urine sample
-
Universitair Ziekenhuis BrusselRecruitingFrailty | Asymptomatic Bacteriuria | Geriatric Syndrome | SIADHBelgium
-
University Hospital, ToulouseCompleted
-
Assistance Publique - Hôpitaux de ParisRecruitingClassification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) (CILLICORIRCM)Ciliopathies | Bardet-Biedl Syndrome | Nephronophthisis | Senior-Loken Syndrome | Joubert Syndrome | Jeune SyndromeFrance
-
GlaxoSmithKlineCompletedInfections, StreptococcalBelgium
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceRecruitingImmune Thrombocytopenia | Autoimmune Hemolytic Anemia | Autoimmune NeutropeniaFrance
-
University Hospital, ToursCompletedMetastatic Prostate Cancer | Circulating Tumor DNAFrance
-
University Hospital, BordeauxActive, not recruitingSystemic Lupus Erythematosus | Systemic SclerodermaFrance
-
University Hospital, BordeauxCompletedRenal Function Disorder | Chronic Renal Diseases
-
The First Affiliated Hospital of Soochow UniversityRecruitingGraft Vs Host DiseaseChina
-
Memorial Sloan Kettering Cancer CenterEARLY LabsRecruiting